Drs. Cierpial and Khayrallah will be developing parallel
groups dedicated to providing a full range of clinical research and regulatory services to
a growing list of both large and small pharmaceutical and biotechnology clients. They will
be handling all aspects of drug development for LRA's clients, from strategic planning for
new compounds to preparation of regulatory submissions.
As LRA has recently moved into designing and implementing clinical trials, Ms. Stanley
will be managing clinical support services, including staff education and training,
standard operating procedures, and quality assurance activities.
"These appointments will facilitate our growth at LRA, while allowing us to
maintain our responsiveness to our clients," said Charles Lineberry, Ph.D., President
of LRA. "These are extremely talented individuals who have contributed greatly to the
outstanding performance of LRA over the last year and their leadership will ensure our
Dr. Moise Khayrallah joined LRA in March, 1996. With nine years of
pharmaceutical experience, he brings to LRA a strong background in clinical research and
project management, as well as statistical strategy and analysis.
Dr. Mark Cierpial came to LRA in June, 1996 with 5 years of prior pharmaceutical
experience in addition to 5 years of NIH-funded postdoctoral training in neurobiology and
Both Drs. Khayrallah and Cierpial have served as project leaders on multiple INDs and
NDAs while at LRA.
Ms. Kimberly Hines Stanley joined LRA in February, 1996 after 5 years in the
pharmaceutical industry. During the last year, Ms. Stanley has been providing scientific
writing services as well as overall project management on clinical trials for LRA's
Lineberry Research Associates is a full-service contract research organization that
provides complete development capabilities, from IND application to NDA approval and
post-marketing, with particular expertise in CNS, anesthesia and analgesia. In
addition to offering proven experience in managing clinical trials, LRA further
differentiates itself by providing its pharmaceutical and biotechnology clients with high
level scientific and regulatory consulting services as well as expertise in scientific
writing and communications.